Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,438 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis Clear all
Completed Not applicable Interventional

Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis

NCT03889327
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Neuropsychological Feedback & Psychoeducation (Cognition), Psychoeducation (Health)
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jun 7, 2026, 6:19 AM EDT
Completed No phase listed Observational

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

NCT06395662
View directory record Official record
Conditions
Radiologically Isolated Syndrome, Multiple Sclerosis
Interventions
Observational
Other
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Other
Eligibility
Not listed
Enrollment
320 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

NCT00792766
View directory record Official record
Conditions
Tuberous Sclerosis, Angiolipoma
Interventions
everolimus (RAD001)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Cerebellar tDCS and Balance Training in PwMS

NCT04391023
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Sham Transcranial Direct Current Stimulation (tDCS), Balance Training, 2 mA Transcranial Direct Current Stimulation, 4 mA Transcranial Direct Current Stimulation
Device · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Jun 7, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 7, 2026, 6:19 AM EDT
Active, not recruiting Phase 4 Interventional

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Not listed Phase 1 Interventional

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

NCT02200718
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NeuroVax, IFA Incomplete Freund's Adjuvant
Biological
Lead sponsor
Immune Response BioPharma, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jun 7, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Diet on Quality of Life in Multiple Sclerosis

NCT05007483
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC, Modified Paleolithic Elimination diet, Time Restricted Olive Oil Based (TROO) Ketogenic Diet, Usual diet with Dietary Guidelines for Americans Diet information
Dietary Supplement · Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jun 7, 2026, 6:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intestinal Immunity in Neurologic Disease

NCT06329453
View directory record Official record
Conditions
Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
Interventions
Colon Tissue Biopsy
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
North Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed No phase listed Observational

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

NCT01547351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ARMS Questionnaire
Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Birmingham, Alabama • Oceanside, California • Hollywood, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Jun 7, 2026, 6:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.

NCT05516537
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Guidelines for Exercise in Multiple Sclerosis (GEMS), FLEX Stretching and Toning Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Intermittent Fasting in Multiple Sclerosis

NCT03539094
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Intermittent fasting
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jun 7, 2026, 6:19 AM EDT
Completed No phase listed Observational

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

NCT04356339
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon-beta-1b (BETASERON, BAY 86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jun 7, 2026, 6:19 AM EDT
Enrolling by invitation No phase listed Observational

CorEvitas Multiple Sclerosis (MS) Registry

NCT03291756
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Self-Directed Positive Psychology Intervention for Newly Diagnosed Multiple Sclerosis

NCT06891937
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Positive psychology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities

NCT00906737
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ankle-bot, Conventional focused ankle therapy
Device · Other
Lead sponsor
Mount Sinai Rehabilitation Hospital
Other
Eligibility
25 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Jun 7, 2026, 6:19 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed No phase listed Observational

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

NCT02099370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jun 7, 2026, 6:19 AM EDT
Completed No phase listed Observational

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study

NCT04061681
View directory record Official record
Conditions
Multiple Sclerosis, Restless Legs Syndrome
Interventions
Behavioral Intervention (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jun 7, 2026, 6:19 AM EDT
Enrolling by invitation Phase 4 Interventional

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

NCT06495593
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 7, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

NCT02710214
View directory record Official record
Conditions
Menopause, Multiple Sclerosis
Interventions
Tissue Selective Estrogen Complex, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 62 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Jun 7, 2026, 6:19 AM EDT